Capital Life Sciences Inves... Net Worth

The estimated Net Worth of Capital Life Sciences Inves... is at least $41.9 Milion dollars as of 4 February 2020. Capital Inves owns over 294,117 units of Arcutis Biotherapeutics Inc stock worth over $41,862,152 and over the last 5 years Capital sold ARQT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Inves ARQT stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Arcutis Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital bought 294,117 units of ARQT stock worth $4,999,989 on 4 February 2020.

The largest trade Capital's ever made was buying 294,117 units of Arcutis Biotherapeutics Inc stock on 4 February 2020 worth over $4,999,989. On average, Capital trades about 294,117 units every 0 days since 2020. As of 4 February 2020 Capital still owns at least 3,979,292 units of Arcutis Biotherapeutics Inc stock.

You can see the complete history of Capital Inves stock trades at the bottom of the page.

Insiders trading at Arcutis Biotherapeutics Inc

Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron a Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.

What does Arcutis Biotherapeutics Inc do?

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.

Complete history of Capital Inves stock trades at Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc executives and stock owners

Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Watanabe,
  President, Chief Executive Officer, Director
• Kenneth Lock,
  Chief Commercial Officer
• Todd Franklin Watanabe M.A.,
  Pres, CEO & Director
• Patricia Turney,
  Senior Vice President - Manufacturing
• Dr. Patrick E. Burnett M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kenneth A. Lock,
  Chief Commercial Officer
• Bhaskar Chaudhuri,
  Independent Director
• Joseph Turner,
  Independent Director
• Ricky Sun,
  Independent Director
• Jonathan Silverstein,
  Independent Director
• Howard Welgus,
  Director
• Halley Gilbert,
  Director
• Terrie Curran,
  Director
• Patrick Burnett,
  Chief Medical Officer
• Keith Klein,
  General Counsel
• Frank Pompilio,
  Vice President - Medical Affairs
• Lynn Navale,
  Vice President - Biometrics
• Charlotte Merritt,
  Vice President - Regulatory Affairs
• Ayisha Jeter,
  Vice President of Market Access
• Meg Elias,
  Vice President - Clinical Operations
• Bethany Dudek,
  Vice President - Quality
• David Berk,
  Vice President - Clinical Development
• Heather Armstrong,
  Vice President of Investor Relations and Corporate Communications
• Kimberly Lathroum,
  Vice President of Marketing
• Jay Ramsinghani,
  Vice President of Commercial Strategy and Operations
• Scott Burrows,
  Vice President - Finance
• John Smither,
  Chief Financial Officer
• David Osborne,
  Co-Founder, Chief Technical Officer
• Patrick Heron,
  Independent Chairman of the Board
• Masaru Matsuda Esq., J.D.,
  Gen. Counsel & Corp. Sec.
• Courtney Barton,
  Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer
• Eric McIntyre,
  Head of Investor Relations
• Dr. David W. Osborne,
  Chief Technical Officer
• Patricia A. Turney,
  Sr. VP of Operations
• Scott L. Burrows,
  CFO & Principal Accounting Officer
• Larry Todd Edwards,
  SVP Chief Commercial Officer
• Daniel Estes,
  Director
• Neha Krishnamohan,
  Director
• David Joseph Topper,
  Chief Financial Officer
• Masaru Matsuda,
  See Remarks
• Capital Life Sciences Inves...,
  
• Advisors Llcorbimed Capital...,
  
• Life Sciences Viii, L.P.Fhm...,
  
• Matthew Richard Moore,
  SVP and Chief Business Officer
• Life Sciences Viii, L.P.Fhm...,
  
• Sue Jean Lin,
  Director
• Keith R Leonard,
  Director
• Life Sciences Viii, L.P.Fhm...,